Neuphoria Therapeutics Inc.
No SEC Form 4 filings for $NEUP in the last 30 days.
See all $NEUP insider activity →Abivax (ABVX) is expected to report a first-half loss of $1.08 per share on revenue of $1.86M. Marygold (MGLD) and Neuphoria (NEUP) reported Q4 losses. Accenture (ACN) partnered with Anthropic, shares up 8.1%. Lobo (LOBO) reported H1 growth, shares up 26.7%.
Neuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029891401ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 23, 2026, BY AND AMONG SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, INC. AND NEUPHORIA THERAPEUTICS INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, IN
Scancell Holdings plc (SCLP.L) and Neuphoria Therapeutics Inc. (NEUP) agreed to an all-share merger, with Scancell shareholders owning 85.5% and Neuphoria shareholders 14.5%. The deal includes up to $89m financing via equity and debt, including BlackRock-managed debt. Proceeds will fund iSCIB1+ Phase 3 milestones, with a primary readout in H2 2028. Shareholder approval is pending.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NEUP (Neuphoria Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NEUP coverage spans financial news, mergers & acquisitions and earnings.
Earnings miss creates slight negative sentiment.
The 8-K discloses NEUP’s entry into a merger agreement, which typically shifts valuation to deal terms and raises deal-completion and financing/timing risk.
The merger provides a defined exit/combination outcome and ties Neuphoria’s equity value to the combined company’s funding and clinical timeline.
Neuphoria shareholders face a takeout/dilution event with CVR-linked upside, making the stock sensitive to milestone definitions and closing conditions.
Potential M&A overhang for NEUP, but terms/timing are unspecified and deal certainty is explicitly denied.
AlphAI scores every news story that mentions NEUP with an AI model for sentiment and relevance, and aggregates insider trades from Neuphoria Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Abivax (ABVX) is expected to report a first-half loss of $1.08 per share on revenue of $1.86M. Marygold (MGLD) and Neuphoria (NEUP) reported Q4 losses. Accenture (ACN) partnered with Anthropic, shares up 8.1%. Lobo (LOBO) reported H1 growth, shares up 26.7%.
2 min readNeuphoria Therapeutics Inc. (NEUP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029891401ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 23, 2026, BY AND AMONG SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, INC. AND NEUPHORIA THERAPEUTICS INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SCANCELL HOLDINGS PLC, SCANCELL MERGER SUB, IN
6 min readScancell Holdings plc (SCLP.L) and Neuphoria Therapeutics Inc. (NEUP) agreed to an all-share merger, with Scancell shareholders owning 85.5% and Neuphoria shareholders 14.5%. The deal includes up to $89m financing via equity and debt, including BlackRock-managed debt. Proceeds will fund iSCIB1+ Phase 3 milestones, with a primary readout in H2 2028. Shareholder approval is pending.
4 min readScancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) announced an all-share merger where Scancell will acquire Neuphoria. The combined company plans to list on Nasdaq under symbol SCLT. Scancell expects up to $89m financing via equity and debt, including $39.1m private placement, about $15m UK equity, and up to $25m debt. Shareholder approval is required.
6 min readNeuphoria Therapeutics (NASDAQ: NEUP) said its board is in discussions with London-listed Scancell Holdings plc about a potential acquisition/combination, with Scancell becoming Nasdaq-listed after any deal closes. The company said there is no certainty of an agreement or transaction terms. Further updates would follow SEC and Nasdaq rules.
4 min readFiles Definitive Proxy Statement for 2025 Annual Meeting of Stockholders ...
2 min readFiles Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote "FOR" BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card
2 min readBURLINGTON, Mass., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Neuphoria Therapeutics Inc. ( "Neuphoria" or the "Company" ) ( Nasdaq: NEUP ) , a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors ( the "Board" ...
2 min readShares of Crown Holdings Inc ( NYSE:CCK ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 adjusted EPS guidance. Crown Holdings reported quarterly adjusted earnings of $2.24 per share, which beat the ...
4 min readAFFIRM-1 trial did not meet primary endpoint or secondary endpoints ...
2 min read
